NEW YORK — The US Food and Drug Administration last week granted Emergency Use Authorizations for a PCR-based SARS-CoV-2 test developed by Clinomics and a combination SARS-CoV-2/influenza point-of-care antigen test from Princeton BioMeditech. In addition, last month it granted EUAs for PCR-based SARS-CoV-2 tests developed by the University of Pennsylvania and Inno Diagnostics Reference Laboratory.